Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Leukoencephalopathies HELP
Based on 12,394 articles published since 2009

These are the 12394 published articles about Leukoencephalopathies that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn Screen. 2018

Regelmann, Molly O / Kamboj, Manmohan K / Miller, Bradley S / Nakamoto, Jon M / Sarafoglou, Kyriakie / Shah, Sejal / Stanley, Takara L / Marino, Rose / Anonymous4711461. ·Division of Pediatric Endocrinology and Diabetes, Children's Hospital at Montefiore, Albert Einstein School of Medicine, Bronx, New York. · Section of Endocrinology, Department of Pediatrics, Nationwide Children's Hospital at The Ohio State University, Columbus, Ohio. · Division of Endocrinology, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota. · Quest Diagnostics Nichols Institute, San Juan Capistrano, California. · Division of Genetics and Metabolism, Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota. · Division of Pediatric Endocrinology and Diabetes, Stanford University, Stanford, California. · Pediatric Endocrine Unit, Massachusetts General Hospital for Children and Harvard Medical School, Boston, Massachusetts. ·J Clin Endocrinol Metab · Pubmed #30289543.

ABSTRACT: Context: Adrenoleukodystrophy (ALD) is a peroxisomal disorder associated with neurologic decompensation and adrenal insufficiency. Newborn screening for ALD has recently been implemented in five states with plans to expand to all 50 states in the United States. Adrenal insufficiency ultimately develops in most males with ALD, but the earliest age of onset is not well established. Objective: These clinical recommendations are intended to address screening for adrenal insufficiency in boys identified to have ALD by newborn screen. Participants: Seven members of the Pediatric Endocrine Society Drug and Therapeutics/Rare Diseases Committee, with clinical experience treating children with ALD and adrenal insufficiency, and a pediatric endocrinologist and laboratory director were selected to be on the working committee. Consensus Process: The authors comprised the working group and performed systematic reviews of the published literature regarding adrenal insufficiency and ALD. The recommendations were reviewed and approved by the larger Pediatric Endocrine Society Drug and Therapeutics/Rare Diseases Committee and then by the Pediatric Endocrine Society Board of Directors. Conclusions: There is limited literature evidence regarding monitoring of evolving adrenal insufficiency in male infants and children with ALD. The recommendations suggest initiating assessment of adrenal function at diagnosis with ALD and regular monitoring to identify boys with adrenal insufficiency in a timely manner and prevent life-threatening adrenal crisis. These recommendations are intended to serve as an initial guide, with the understanding that additional experience will inform future guidelines.

2 Guideline Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. 2018

Skrobot, Olivia A / Black, Sandra E / Chen, Christopher / DeCarli, Charles / Erkinjuntti, Timo / Ford, Gary A / Kalaria, Rajesh N / O'Brien, John / Pantoni, Leonardo / Pasquier, Florence / Roman, Gustavo C / Wallin, Anders / Sachdev, Perminder / Skoog, Ingmar / Anonymous1341217 / Ben-Shlomo, Yoav / Passmore, Anthony P / Love, Seth / Kehoe, Patrick G. ·Translational Health Sciences, University of Bristol, Bristol, UK. · Sunnybrook Research Institute, University of Toronto, Ontario, Canada. · Department of Pharmacology, National University of Singapore, Singapore. · Department of Neurology and Center for Neuroscience, University of California at Davis, Sacramento, California, USA. · Neurology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. · Divison of Medical Sciences, Oxford University, Oxford, UK. · Institute of Neuroscience, Newcastle University, Newcastle, UK. · Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK. · NEUROFARBA Department, University of Florence, Florence, Italy. · Inserm U1171, University of Lille, Lille, France. · Methodist Neurological Institute, Houston, Texas, USA. · Memory Clinic at Department of Neuropsychiatry, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. · School of Psychiatry, University of New South Wales, Sydney, Australia; Neuropsychiatric Institute, Prince of Wales Hospital, Randwick, New South Wales, Australia. · Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden. · Population Health Sciences, University of Bristol, Bristol, UK. · Institute of Clinical Sciences, Block B, Queens University Belfast, Belfast, UK. · Translational Health Sciences, University of Bristol, Bristol, UK. Electronic address: patrick.kehoe@bristol.ac.uk. ·Alzheimers Dement · Pubmed #29055812.

ABSTRACT: INTRODUCTION: Progress in understanding and management of vascular cognitive impairment (VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different assessment protocols. A large multinational group of clinicians and researchers participated in a two-phase Vascular Impairment of Cognition Classification Consensus Study (VICCCS) to agree on principles (VICCCS-1) and protocols (VICCCS-2) for diagnosis of VCI. We present VICCCS-2. METHODS: We used VICCCS-1 principles and published diagnostic guidelines as points of reference for an online Delphi survey aimed at achieving consensus on clinical diagnosis of VCI. RESULTS: Six survey rounds comprising 65-79 participants agreed guidelines for diagnosis of VICCCS-revised mild and major forms of VCI and endorsed the National Institute of Neurological Disorders-Canadian Stroke Network neuropsychological assessment protocols and recommendations for imaging. DISCUSSION: The VICCCS-2 suggests standardized use of the National Institute of Neurological Disorders-Canadian Stroke Network recommendations on neuropsychological and imaging assessment for diagnosis of VCI so as to promote research collaboration.

3 Guideline Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. 2017

Adang, Laura A / Sherbini, Omar / Ball, Laura / Bloom, Miriam / Darbari, Anil / Amartino, Hernan / DiVito, Donna / Eichler, Florian / Escolar, Maria / Evans, Sarah H / Fatemi, Ali / Fraser, Jamie / Hollowell, Leslie / Jaffe, Nicole / Joseph, Christopher / Karpinski, Mary / Keller, Stephanie / Maddock, Ryan / Mancilla, Edna / McClary, Bruce / Mertz, Jana / Morgart, Kiley / Langan, Thomas / Leventer, Richard / Parikh, Sumit / Pizzino, Amy / Prange, Erin / Renaud, Deborah L / Rizzo, William / Shapiro, Jay / Suhr, Dean / Suhr, Teryn / Tonduti, Davide / Waggoner, Jacque / Waldman, Amy / Wolf, Nicole I / Zerem, Ayelet / Bonkowsky, Joshua L / Bernard, Genevieve / van Haren, Keith / Vanderver, Adeline / Anonymous700918. ·Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. · Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. · Center for Translational Science, Children's National Medical Center, Washington, DC, USA; Department of Physical Medicine and Rehabilitation, Children's National Medical Center, Washington, DC, USA. · Department of Pediatrics, Children's National Medical Center, Washington, DC, USA; Complex Care Program, Children's National Medical Center, Washington, DC, USA. · Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Children's National Medical Center, Washington, DC, USA. · Servicio de Neurología Infantil, Hospital Universitario Austral, Buenos Aires, Argentina. · Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. · Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA, USA. · The Hugo W. Moser Research Institute, The Kennedy Krieger Institute, Baltimore, MD, USA. · Rare Disease Institute, Children's National Medical Center, Washington, DC, USA. · Complex Care Program, Children's National Medical Center, Washington, DC, USA. · Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. · Pediatric Multiple Sclerosis Center, Women and Children's Hospital, Buffalo, NY, USA. · Division of Pediatric Neurology, Emory University, Atlanta, GA, USA. · Department of Pediatrics, Children's National Medical Center, Washington, DC, USA. · Division of Endocrinology and Diabetes, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. · Autism Spectrum Disorders Center, Women and Children's Hospital, Buffalo, NY, USA. · Psychiatric Social Work Program, The Kennedy Krieger Institute, Baltimore, MD, USA. · Hunter James Kelly Research Institute, Buffalo, NY, USA. · Department of Paediatrics, Murdoch Children's Research Institute, University of Melbourne, Melbourne, Australia. · Neurogenetics, Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA. · Division of Child and Adolescent Neurology, Departments of Neurology and Pediatrics, Mayo Clinic, Rochester, MN, USA. · Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA. · MLD Foundation, West Linn, OR, USA. · Department of Child Neurology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. · Hunter's Hope Foundation, Orchard Park, NY, USA. · Department of Child Neurology, VU University Medical Centre and Amsterdam Neuroscience, Amsterdam, The Netherlands. · E. Wolfson Medical Center, Tel Aviv, Israel. · Department of Pediatrics, Division of Pediatric Neurology, University of Utah School of Medicine, Salt Lake City, UT, USA. · Department of Neurology and Neurosurgery, McGill University, Montreal, Canada; Department of Pediatrics, McGill University, Montreal, Canada; Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Center, Montreal, Canada; Child Health and Human Development Program, Research Institute of the McGill University Health Center, Montreal, Canada. · Department of Neurology, Lucile Packard Children's Hospital and Stanford University School of Medicine, Stanford, CA, USA. · Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Center for Translational Science, Children's National Medical Center, Washington, DC, USA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. Electronic address: vandervera@email.chop.edu. ·Mol Genet Metab · Pubmed #28863857.

ABSTRACT: Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

4 Guideline Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. 2015

Vogel, B H / Bradley, S E / Adams, D J / D'Aco, K / Erbe, R W / Fong, C / Iglesias, A / Kronn, D / Levy, P / Morrissey, M / Orsini, J / Parton, P / Pellegrino, J / Saavedra-Matiz, C A / Shur, N / Wasserstein, M / Raymond, G V / Caggana, M. ·Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA. Electronic address: beth.vogel@health.ny.gov. · Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA. · Jacobs Equity Management Personalized Genomic Medicine Program, Goryeb Pediatrics Genetics and Metabolism, Morristown, NJ, USA. · Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA. · Division of Genetics, Women and Children's Hospital of Buffalo, Buffalo, NY, USA. · New York Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. · New York Medical College, Valhalla, NY, USA. · Center for Inherited Medical Disorders, Children's Hospital at Montefiore, Bronx, NY, USA. · Division of Genetics, Stony Brook Long Island Children's Hospital, Stony Brook, NY, USA. · Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, NY, USA. · Albany Medical Center, Albany, NY, USA. · Division of Medical Genetics, Division of Genomic Sciences, Mount Sinai Medical Center, New York, NY, USA. · Department of Neurology, University of Minnesota Medical Center, Minneapolis, MN, USA. ·Mol Genet Metab · Pubmed #25724074.

ABSTRACT: PURPOSE: To describe a diagnostic protocol, surveillance and treatment guidelines, genetic counseling considerations and long-term follow-up data elements developed in preparation for X-linked adrenoleukodystrophy (X-ALD) newborn screening in New York State. METHODS: A group including the director from each regional NYS inherited metabolic disorder center, personnel from the NYS Newborn Screening Program, and others prepared a follow-up plan for X-ALD NBS. Over the months preceding the start of screening, a series of conference calls took place to develop and refine a complete newborn screening system from initial positive screen results to long-term follow-up. RESULTS: A diagnostic protocol was developed to determine for each newborn with a positive screen whether the final diagnosis is X-ALD, carrier of X-ALD, Zellweger spectrum disorder, acyl CoA oxidase deficiency or D-bifunctional protein deficiency. For asymptomatic males with X-ALD, surveillance protocols were developed for use at the time of diagnosis, during childhood and during adulthood. Considerations for timing of treatment of adrenal and cerebral disease were developed. CONCLUSION: Because New York was the first newborn screening laboratory to include X-ALD on its panel, and symptoms may not develop for years, long-term follow-up is needed to evaluate the presented guidelines.

5 Guideline Diabetes and dementia in older people: a Best Clinical Practice Statement by a multidisciplinary National Expert Working Group. 2014

Sinclair, A J / Hillson, R / Bayer, A J / Anonymous4140803. ·Institute of Diabetyes for Older People (IDOP), University of Bedfordshire, Luton. ·Diabet Med · Pubmed #25131194.

ABSTRACT: Both dementia and diabetes mellitus are long-term disabling conditions and each may be a co-morbidity of the other. Type 2 diabetes is associated with a 1.5- to 2-fold higher risk of dementia. Diabetes also may occur for the first time in many individuals with mental ill health, including cognitive impairment and dementia, and this may complicate management and lead to difficulties in self-care. Case finding is often poor for cognitive impairment in medical settings and for diabetes in mental health settings and this needs to be addressed in the development of care pathways for both conditions. Many other deficiencies in quality care (both for dementia and diabetes) currently exist, but we hope that this Best Clinical Practice Statement will provide a platform for further work in this area. We have outlined the key steps in an integrated care pathway for both elements of this clinical relationship, produced guidance on identifying each condition, dealt with the potentially hazardous issue of hypoglycaemia, and have outlined important competencies required of healthcare workers in both medical/diabetes and mental health settings to enhance clinical care.

6 Guideline Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists. 2014

Broadley, Simon A / Barnett, Michael H / Boggild, Mike / Brew, Bruce J / Butzkueven, Helmut / Heard, Robert / Hodgkinson, Suzanne / Kermode, Allan G / Lechner-Scott, Jeannette / Macdonell, Richard A L / Marriott, Mark / Mason, Deborah F / Parratt, John / Reddel, Stephen W / Shaw, Cameron P / Slee, Mark / Spies, Judith / Taylor, Bruce V / Carroll, William M / Kilpatrick, Trevor J / King, John / McCombe, Pamela A / Pollard, John D / Willoughby, Ernest / Anonymous2940799. ·School of Medicine, Griffith University, Gold Coast Campus, QLD 4222, Australia; Department of Neurology, Gold Coast University Hospital, Southport, QLD, Australia. Electronic address: simon.broadley@griffith.edu.au. · Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia. · Department of Neurology, The Townsville Hospital, Douglas, QLD, Australia. · Department of Neurology and St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia. · Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia; Department of Neurology, Eastern Health and Monash University, 2/5 Arnold Street, Box Hill VIC 3128, Australia. · Westmead Clinical School, University of Sydney, NSW, Australia. · South Western Sydney Clinical School, University of New South Wales, NSW, Australia. · Centre for Neuromuscular and Neurological Disorders, University of Western Australia, WA, Australia. · Hunter Medical Research Institute, The University of Newcastle, New Lambton, NSW, Australia. · Department of Neurology, Austin Health, Heidelberg, VIC, Australia. · Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia. · Department of Neurology, Christchurch Hospital, Christchurch, New Zealand. · Central Clinical School, University of Sydney, NSW, Australia. · School of Medicine, Deakin University, VIC, Australia. · Flinders Medical Centre, Flinders University, SA, Australia. · Menzies Research Institute, University of Tasmania, TAS, Australia. · Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia. · University of Queensland Centre for Clinical Research, QLD, Australia. · Department of Neurology, Auckland City Hospital, Auckland, New Zealand. ·J Clin Neurosci · Pubmed #24993136.

ABSTRACT: In this third and final part of our review of multiple sclerosis (MS) treatment we look at the practical day-to-day management issues that are likely to influence individual treatment decisions. Whilst efficacy is clearly of considerable importance, tolerability and the potential for adverse effects often play a significant role in informing individual patient decisions. Here we review the issues surrounding switching between therapies, and the evidence to assist guiding the choice of therapy to change to and when to change. We review the current level of evidence with regards to the management of women in their child-bearing years with regards to recommendations about treatment during pregnancy and whilst breast feeding. We provide a summary of recommended pre- and post-treatment monitoring for the available therapies and review the evidence with regards to the value of testing for antibodies which are known to be neutralising for some therapies. We review the occurrence of adverse events, both the more common and troublesome effects and those that are less common but have potentially much more serious outcomes. Ways of mitigating these risks and managing the more troublesome adverse effects are also reviewed. Finally, we make specific recommendations with regards to the treatment of MS. It is an exciting time in the world of MS neurology and the prospects for further advances in coming years are high.

7 Guideline Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. 2014

Sachdev, Perminder / Kalaria, Raj / O'Brien, John / Skoog, Ingmar / Alladi, Suvarna / Black, Sandra E / Blacker, Deborah / Blazer, Dan G / Chen, Christopher / Chui, Helena / Ganguli, Mary / Jellinger, Kurt / Jeste, Dilip V / Pasquier, Florence / Paulsen, Jane / Prins, Niels / Rockwood, Kenneth / Roman, Gustavo / Scheltens, Philip / Anonymous1680788. ·*Centre for Healthy Brain Ageing, School of Psychiatry, University of New South Wales †Neuropsychiatric Institute, Prince of Wales Hospital, Sydney, NSW, Australia ‡Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, Tyne and Wear §Department of Psychiatry, University of Cambridge, Cambridge, UK ∥Department of Psychiatry and Neurochemistry, University of Gothenburg, Göteborg, Sweden ¶Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India #University of Toronto and Sunnybrook Health Sciences Centre, Toronto, ON §§§Dalhousie University, Halifax, NS, Canada **Departments of Epidemiology, Harvard Medical School, Boston, MA ††Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC ‡‡Memory Aging and Cognition Centre, National University Health System, Singapore §§Department of Neurology, University of Southern California and Keck School of Medicine, Los Angeles, CA ∥∥University of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA ¶¶Institute of Clinical Neurobiology, Vienna, Austria ##Department of Psychiatry, University of California, San Diego, CA ***University Lille Nord de France UDSL and Memory Clinic, CHU, Lille, France †††The Carver College of Medicine, The University of Iowa, Iowa City, IA ‡‡‡Alzheimer Centre and Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands ∥∥∥Methodist Neurological Institute, Houston, TX. ·Alzheimer Dis Assoc Disord · Pubmed #24632990.

ABSTRACT: BACKGROUND: Several sets of diagnostic criteria have been published for vascular dementia since the 1960s. The continuing ambiguity in vascular dementia definition warrants a critical reexamination. METHODS: Participants at a special symposium of the International Society for Vascular Behavioral and Cognitive Disorders (VASCOG) in 2009 critiqued the current criteria. They drafted a proposal for a new set of criteria, later reviewed through multiple drafts by the group, including additional experts and the members of the Neurocognitive Disorders Work Group of the fifth revision of Diagnostic and Statistical Manual (DSM-5) Task Force. RESULTS: Cognitive disorders of vascular etiology are a heterogeneous group of disorders with diverse pathologies and clinical manifestations, discussed broadly under the rubric of vascular cognitive disorders (VCD). The continuum of vascular cognitive impairment is recognized by the categories of Mild Vascular Cognitive Disorder, and Vascular Dementia or Major Vascular Cognitive Disorder. Diagnostic thresholds are defined. Clinical and neuroimaging criteria are proposed for establishing vascular etiology. Subtypes of VCD are described, and the frequent cooccurrence of Alzheimer disease pathology emphasized. CONCLUSIONS: The proposed criteria for VCD provide a coherent approach to the diagnosis of this diverse group of disorders, with a view to stimulating clinical and pathologic validation studies. These criteria can be harmonized with the DSM-5 criteria such that an international consensus on the criteria for VCD may be achieved.

8 Guideline International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. 2013

Krupp, Lauren B / Tardieu, Marc / Amato, Maria Pia / Banwell, Brenda / Chitnis, Tanuja / Dale, Russell C / Ghezzi, Angelo / Hintzen, Rogier / Kornberg, Andrew / Pohl, Daniela / Rostasy, Kevin / Tenembaum, Silvia / Wassmer, Evangeline / Anonymous2050755. ·Lourie Center for Pediatric MS. Stony Brook University Medical Center, USA. lauren.krupp@stonybrook.edu ·Mult Scler · Pubmed #23572237.

ABSTRACT: BACKGROUND: There has been tremendous growth in research in pediatric multiple sclerosis (MS) and immune mediated central nervous system demyelinating disorders since operational definitions for these conditions were first proposed in 2007. Further, the International Pediatric Multiple Sclerosis Study Group (IPMSSG), which proposed the criteria, has expanded substantially in membership and in its international scope. OBJECTIVE: The purpose of this review is to revise the 2007 definitions in order to incorporate advances in delineating the clinical and neuroradiologic features of these disorders. METHODS: Through a consensus process, in which input was sought from the 150 members of the Study Group, criteria were drafted, revised and finalized. Final approval was sought through a web survey. RESULTS: Revised criteria are proposed for pediatric acute disseminated encephalomyelitis, pediatric clinically isolated syndrome, pediatric neuromyelitis optica and pediatric MS. These criteria were approved by 93% or more of the 56 Study Group members who responded to the final survey. CONCLUSIONS: These definitions are proposed for clinical and research purposes. Their utility will depend on the outcomes of their application in prospective research.

9 Guideline EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012

Sorbi, S / Hort, J / Erkinjuntti, T / Fladby, T / Gainotti, G / Gurvit, H / Nacmias, B / Pasquier, F / Popescu, B O / Rektorova, I / Religa, D / Rusina, R / Rossor, M / Schmidt, R / Stefanova, E / Warren, J D / Scheltens, P / Anonymous1560734. ·Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. sorbi@unifi.it ·Eur J Neurol · Pubmed #22891773.

ABSTRACT: BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.

10 Guideline Nationwide survey of Alexander disease in Japan and proposed new guidelines for diagnosis. 2011

Yoshida, Tomokatsu / Sasaki, Masayuki / Yoshida, Mari / Namekawa, Michito / Okamoto, Yuji / Tsujino, Seiichi / Sasayama, Hiroshi / Mizuta, Ikuko / Nakagawa, Masanori / Anonymous2000693. ·Department of Neurology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kajii-chou 465, Kamigyo-ku, Kyoto 602-0841, Japan. toyoshid@koto.kpu-m.ac.jp ·J Neurol · Pubmed #21533827.

ABSTRACT: Alexander disease (AxD) is a rare neurodegenerative disorder characterized by white matter degeneration and formation of cytoplasmic inclusions. Glial fibrillary acidic protein (GFAP) mutations have been reported in various forms of AxD since 2001. However, a definitive diagnosis remains difficult because of uncertain prevalence, and different clinical features seen in infantile AxD and adult AxD may lead to confusion and misdiagnosis. Here we report an epidemiological study conducted in Japan. Two nationwide questionnaire-based surveys were conducted using tentative diagnostic criteria. We gathered information regarding prevalence, neurological findings, magnetic resonance imaging (MRI) findings, electrophysiological findings, genetic information, and the results of therapeutic interventions and home care. Prevalence of various forms of AxD was determined as 27.3% (infantile), 24.2% (juvenile), and 48.5% (adult). Prevalence of AxD in Japan was estimated to be approximately 1 case per 2.7 million individuals. The main characteristics of infantile and juvenile AxD include delayed psychomotor development or mental retardation, convulsions, macrocephaly, and predominant cerebral white matter abnormalities in the frontal lobe on brain MRI. The main characteristics of adult AxD include bulbar signs, muscle weakness with hyperreflexia, and signal abnormalities and/or atrophy of medulla oblongata and cervical spinal cord on MRI. To ensure correct diagnosis of AxD, the physician should understand the importance of the process of GFAP genetic testing, which provides definitive diagnosis. Therefore, we propose new clinical guidelines for diagnosing AxD based on simplified classifications: cerebral AxD (type 1), bulbospinal AxD (type 2), and intermediate form (type 3).

11 Guideline Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. 2011

Ghezzi, A / Grimaldi, L M E / Marrosu, M G / Pozzilli, C / Comi, G / Bertolotto, A / Trojano, M / Gallo, P / Capra, R / Centonze, D / Millefiorini, E / Sotgiu, S / Brescia Morra, V / Amato, M P / Lugaresi, A / Mancardi, G / Caputo, D / Montanari, E / Provinciali, L / Durelli, L / Bergamaschi, R / Bellantonio, P / Tola, M R / Cottone, S / Savettieri, G / Tedeschi, G / Anonymous90684. ·U.O. Neurologia II, Centro Studi Sclerosi Multipla, Ospedale di Gallarate, Gallarate, Italy. angelo.ghezzi@aogallarate.it ·Neurol Sci · Pubmed #21234775.

ABSTRACT: Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

12 Editorial From Sardinia to Japan: update on the role of MAP in multiple sclerosis. 2019

Cossu, Davide / Yokoyama, Kazumasa / Nobutaka, Hattori / Sechi, Leonardo. ·Department of Neurology, Juntendo University, Tokyo, Japan. · Advanced Research Institute for Health Science, Juntendo University, Tokyo, Japan. · Microbiology Section, Department of Biomedical Sciences, University of Sassari, Italy. ·Future Microbiol · Pubmed #31148467.

ABSTRACT: -- No abstract --

13 Editorial Can Immune Checkpoint Inhibitors Keep JC Virus in Check? 2019

Koralnik, Igor J. ·From the Department of Neurological Sciences, Rush University Medical Center, Chicago. ·N Engl J Med · Pubmed #30969502.

ABSTRACT: -- No abstract --

14 Editorial Posterior Reversible Encephalopathy Syndrome: Not Always Posterior, Not always Reversible. 2019

Gupta, Vishal. ·Associate Professor, Medical Intensive Care Unit, Department of Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra. ·J Assoc Physicians India · Pubmed #30935164.

ABSTRACT: -- No abstract --

15 Editorial US Supreme Court should prevent execution of murderer who no longer remembers his crime. 2018

Anonymous2180964. · ·Nature · Pubmed #30283113.

ABSTRACT: -- No abstract --

16 Editorial Medical Plants and Immunological Regulation. 2018

Xiao, Cheng / Guan, Qingdong / Tan, Yong / Hou, Lifei / Xie, Wuxiang. ·Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing 100029, China. · Cellular Therapy Laboratory, CancerCare Manitoba, Winnipeg, MB, Canada R3A 1R9. · Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. · Program in Cellular and Molecular Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. · Peking University Clinical Research Institute, Peking University Health Science Center, Beijing 100191, China. ·J Immunol Res · Pubmed #30009189.

ABSTRACT: -- No abstract --

17 Editorial JC Virus Infection: An Expanding Spectrum of Neurological Disorders. 2018

Jackson, Alan C. ·Departments of Internal Medicine (Neurology) and of Medical Microbiology,University of Manitoba,WinnipegManitoba,Canada. ·Can J Neurol Sci · Pubmed #29923467.

ABSTRACT: -- No abstract --

18 Editorial Relapsing acute disseminated encephalomyelitis followed by optic neuritis in children; a clinical entity associated with anti-MOG antibody. 2018

Brilot, F. ·Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW, Australia. · Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia. · Applied Medical Sciences, The University of Sydney, Sydney, NSW, Australia. ·Eur J Neurol · Pubmed #29790244.

ABSTRACT: -- No abstract --

19 Editorial Editors' Welcome: Pregnancy and progressive multifocal leukoencephalopathy. 2018

Levy, Michael / Giovannoni, Gavin / Hawkes, Chris / Waubant, Emmanuelle. · ·Mult Scler Relat Disord · Pubmed #29724377.

ABSTRACT: -- No abstract --

20 Editorial Progressive Multifocal Leukoencephalopathy Lesions and JC Virus: The Limits and Value of Imaging. 2018

Major, Eugene O. ·Molecular Medicine and Neuroscience, Division of Neuroimmunology and Neurovirology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. ·JAMA Neurol · Pubmed #29532060.

ABSTRACT: -- No abstract --

21 Editorial Does upper respiratory infection exacerbate symptoms of multiple sclerosis? 2018

Ryder, Emily / Steelman, Andrew J. ·Department of Animal Sciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA. · Neuroscience Program, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA. · Division of Nutritional Sciences, University of Illinois Urbana-Champaign, Urbana, IL 61801, USA. ·Future Microbiol · Pubmed #29517364.

ABSTRACT: -- No abstract --

22 Editorial Survivor's Remorse: Is There an Increased Risk of Dementia After Surviving a Myocardial Infarction? 2018

Gottesman, Rebecca F. ·Departments of Neurology and Epidemiology, Johns Hopkins University, Baltimore, MD. rgottesm@jhmi.edu. ·Circulation · Pubmed #29431660.

ABSTRACT: -- No abstract --

23 Editorial Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy. 2018

van Rappard, Diane F / de Vries, Annelou L C / Oostrom, Kim J / Boelens, Jaap Jan / Hollak, Carla E M / van der Knaap, Marjo S / Wolf, Nicole I. ·Center for Childhood White Matter Disorders, VU University Medical Centre and Amsterdam Neuroscience, Amsterdam. · Center of Expertise on Gender Dysphoria, VU University Medical Center. · VU University Medical Center Amsterdam. · Blood and Marrow Transplantation Program, University Medical Center Utrecht, the Netherlands. · Division of Endocrinology and Metabolism, Academic Medical Center Amsterdam. · Center for Childhood White Matter Disorders, VU University Medical Centre and Amsterdam Neuroscience, Amsterdam; Center for Neurogenomics and Cognitive Research, VU University. · Center for Childhood White Matter Disorders, VU University Medical Centre and Amsterdam Neuroscience, Amsterdam. Electronic address: n.wolf@vumc.nl. ·J Am Acad Child Adolesc Psychiatry · Pubmed #29413149.

ABSTRACT: -- No abstract --

24 Editorial Progressive multifocal leukoencephalopathy: Are you aware of it? 2018

Clifford, David B / Berger, Thomas. ·From the Departments of Neurology and Medicine (D.B.C.), Washington University in St. Louis, MO · and Clinical Department of Neurology (T.B.), Medical University of Innsbruck, Austria. ·Neurology · Pubmed #29321230.

ABSTRACT: -- No abstract --

25 Editorial Using the Telephone Interview for Cognitive Status and Telephone Montreal Cognitive Assessment for Evaluating Vascular Cognitive Impairment: Promising Call or Put on Hold? 2017

Cohen, Ronald A / Alexander, Gene E. ·From the Center for Cognitive Aging and Memory Clinical Translational Research and Department of Clinical and Health Psychology, University of Florida, Gainesville (R.A.C.) · and Departments of Psychology and Psychiatry, Neuroscience and Physiological Sciences Graduate Interdisciplinary Programs, BIO5 Institute, and Evelyn F. Mcknight Brain Institute, University of Arizona, Tucson (G.E.A.). ·Stroke · Pubmed #29042491.

ABSTRACT: -- No abstract --